Marinus Pharma (MRNS) Highlights Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. META
4. DPZ
5. IBM
6. CNC
7. KFY
8. SPY
9. MU
10. ENRD

Go back to Marinus Pharma (MRNS) Highlights Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus

Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual Meeting

December 7, 2019 12:01 AM EST

100% of evaluable patients in target dose had no relapse during the four-week follow-up period

Independent objective EEG seizure analysis confirms target dose

Ganaxolone effective regardless of prior AED treatment and across diverse disease etiologies for RSE

KOL call and live webcast on Monday, December 9th at 7:15am ET

RADNOR, Pa., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:... More